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Research in Context 
 
Evidence before this study 
 
There is increasing recognition that many individuals surviving tuberculosis experience substantial 
morbidity, are at increased risk of developing tuberculosis again, and have higher all cause mortality 
than those who have never had tuberculosis. Tuberculosis can also lead to stigma and can impact on 
the finances of the family beyond the end of treatment. These impacts have been reviewed, including 
a systematic review and meta-analysis of relative mortality. In order to identify and support these 
survivors, a first step is to quantify the number alive today that have had tuberculosis.  
 
van Kampen and colleagues undertook a broad systematic scoping review which searched for articles 
on post-tuberculosis morbidity, published between 1990 and 2018, finding a rapidly accelerating 
literature in this area. To supplement this therefore, we searched the PubMed from 2018 onwards with 
the terms: (((cure* OR sequel* OR recovered OR resolved OR former OR "history of" OR survivor* 
OR prior OR healed OR previous* OR post-treatment OR “completed treatment” OR “after 
treatment”) AND (tubercul* OR TB)) OR (post-tuberculosis OR posttuberculosis OR posttubercular 
OR post-tubercular OR post-TB OR treated tubercul* OR “treated pulmonary TB” OR “treated 
pulmonary tuberculosis” OR “treated tb”)) AND (“burden” OR number OR “life year” OR prevalen* 
OR estimate*) AND 2018:2020[dp]. This search yielded 2,804 results (8/8/2020). We sifted these 
search results and the articles included by van Kampen and colleagues for relevance. In 2011, 
Denning and colleagues used a simple estimation approach to quantify the global burden of chronic 
pulmonary aspergillosis in tuberculosis survivors over a five year period (and subsequently in 4 
particular countries). We found no articles estimating the numbers of tuberculosis survivors around 
the world, nor the cumulative life years lived after tuberculosis disease. 
 
Added value of this study 
 
Our analysis estimates that 363 million people developed tuberculosis between 1980 and 2019, of 
which 155 million are alive today. A total of 3.5 billion life years were lived in this period by people 
who had developed tuberculosis. We found that 27 million of these individuals were diagnosed and 
treated in the last five years, representing a population that is amenable to identification, screening 
and potential therapeutic intervention. Almost half of those diagnosed in the last five years (12 
million) were treated in the South-East Asia World Health Organization region and globally 6% were 
living with HIV at the time of their tuberculosis diagnosis.    
 
Implications of all the available evidence 
 
Tuberculosis programmes have generally focussed on finding and diagnosing cases of tuberculosis 
and supporting these individuals to the end of treatment. Our data suggest that there is a large 
population of tuberculosis survivors who are alive today who would benefit from screening for post 
tuberculosis consequences and then, if necessary medical intervention. Many might also need 
financial or social support. More research is required in this field to better understand the 
pathophysiology, spectrum and burden of post-tuberculosis morbidity and to develop improved 









People who survive tuberculosis continue to experience clinical and societal consequences after 
recovery, including increased risks of recurrent tuberculosis, premature death, reduced lung function, 
and ongoing stigma. We aimed to describe the magnitude of this issue by estimating the number of 




We estimated the number of people who developed tuberculosis during 1980-2019 and survived until 
2020. Numbers surviving treatment were based on country-level data on tuberculosis case 
notifications reported to the World Health Organization (WHO), excluding people who died during 
treatment. Numbers surviving untreated tuberculosis were based on the difference between WHO 
country-level incidence estimates and notifications, with published age- and HIV-stratified case 
fatality ratios applied. Post-tuberculosis life tables were developed for each country-year, using 
United Nations World Population Prospects 2019 mortality rates and published post-tuberculosis 
mortality hazard ratios.  
   
Findings 
 
Between 1980 and 2019 we estimate that 363 (95% uncertainty interval [UI] 287 - 438) million 
people developed tuberculosis, of whom 172 (95%UI 169 - 174) million were treated.  Individuals 
who developed tuberculosis since 1980 experienced a total of 3.5 (95%UI 3.0 - 3.9)  billion life-years 
post-tuberculosis, with survivors of paediatric tuberculosis contributing 12% (95%UI 7 - 17%) of 
these life-years.  We estimate that 155 (95%UI 138 - 171) million tuberculosis survivors were alive in 
2020.  The South-East Asia region had the largest proportion of tuberculosis survivors (47%).  We 
estimate that 27 (95%UI 26 - 29) million tuberculosis survivors alive in 2020 were treated within the 




The number of tuberculosis survivors alive today is over ten times the estimated annual tuberculosis 
incidence. Interventions to alleviate respiratory morbidity, screen for and prevent recurrent 
tuberculosis, and reduce stigma should be immediately prioritised for recently treated tuberculosis 
survivors.   
 
Funding 





An estimated ten million people develop tuberculosis disease annually, with around 70% receiving 
treatment.1 While tuberculosis is curable, tuberculosis survivors continue to experience clinical and 
societal consequences of the disease even after recovery. Despite this, health systems do not generally 
focus attention on people affected by tuberculosis after treatment completion. The World Health 
Organization (WHO) reporting requirements for tuberculosis focus on diagnosis and treatment, and 
WHO epidemiologic estimates and programmatic targets set for countries both fall within these areas. 
There are limited data available that focus on people who have survived tuberculosis disease or the 
impact that tuberculosis continues to have on their lives.   
 
There is increasing recognition that tuberculosis exerts an impact on survivors that extends beyond 
their tuberculosis episode. Those who survive tuberculosis are not only at increased risk of developing 
tuberculosis again compared to those who have never had tuberculosis,2  but they have increased all-
cause mortality2,3 and reduced life expectancy4 irrespective of adequate tuberculosis treatment. 
Pulmonary tuberculosis is increasingly recognised as an important risk factor for chronic respiratory 
disease. Persistence of abnormal spirometry (airway obstruction and low forced vital capacity 
patterns) and chronic or recurrent symptoms beyond cure are well described.5–7  Even mild and 
subclinical impairment in forced expiratory volume blown in one second (FEV1) has been shown to 
be an independent predictor of mortality and cardiovascular disease in addition to respiratory 
hospitalisation.8  Reductions in health-related quality of life and exercise tolerance have been noted in 
individuals following an episode of tuberculosis disease despite successful treatment or cure.9  
Although data are lacking, pulmonary tuberculosis early in life could have significant long-term 
consequences as prenatal and early childhood are the most critical periods for lung growth and 
development. Individuals surviving other forms of tuberculosis, particularly tuberculosis meningitis, 
frequently experience ongoing neurological morbidity,10 and many tuberculosis survivors have 
psychological morbidity associated with their disease and treatment.  
 
The social and economic impact of tuberculosis also persists well beyond the end of treatment. 
Communities may continue to stigmatise or socially isolate tuberculosis survivors, diminishing 
marriage prospects for young women or prompting divorce.11,12 Tuberculosis can drive families 
deeper into poverty both by requiring out-of-pocket expenditure for medical and non-medical costs, as 
well as by reducing income during tuberculosis treatment.13 The socioeconomic impact of 
impoverishment on both the individual and the household may last for many successive years, with 
children being at high risk of malnutrition or discontinued education.14  
 
The first step to addressing the challenges faced by tuberculosis survivors is to determine the number 
of people affected, their basic demographic characteristics, and where to find them. This information 
is necessary to help health systems plan interventions directed at mitigating the lasting effects of 
tuberculosis on survivors. In this study we aimed to model the number of individuals globally who 
have developed tuberculosis since 1980, the number who have survived to the present day, and the 




Our analysis considered 190 countries, comprising 99% of the global population for 2020 and 98% of 
estimated 2018 tuberculosis incidence. We sought to characterise those alive in 2020 of those who 
had survived tuberculosis since 1980, the first year of tuberculosis notification data collated by WHO. 
An overview of the methodology is presented in Figure 1, and more detailed methods are provided in 
an online Appendix. 
Numbers surviving anti-tuberculosis treatment episodes 
We used country data collated by the WHO on notified tuberculosis between 1980 and 2018. 
Notifications for India were altered to account for two major changes in reporting: a change in 
definition in 1991 resulting in a drop, and the wider inclusion of the private sector from 2013. We 
scaled Indian notifications by a single factor prior to 1991 and a linearly increasing factor for the 
years 1991 - 2013 (see Appendix). Missing notification counts (including 2019) were imputed using a 
Kalman smoother. To avoid double counting of recurrent tuberculosis, notifications were scaled to 
represent only new tuberculosis cases using country-specific averages of the ratio between new and 
relapse notifications, or regional averages where data were lacking. Country-specific averages of the 
proportion of cases notified in each sex and age category were used to disaggregate notifications in 
each year by sex and ages 0-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, and 65+ years, using averages 
where data were lacking. WHO-collated treatment outcome data were aggregated for each country 
across years and type of tuberculosis disease, and taken not to vary by age, sex or HIV/ART-status. 
The fraction of cases surviving treatment was constructed assuming the same proportion of death 
among those lost-to-follow-up as among those with follow-up. 
 
To disaggregate the numbers surviving anti-tuberculosis treatment (ATT) into single year age groups, 
we made use of population estimates for each country from the United Nations World Population 
Prospects 2019 (WPP19), which we linearly interpolated to single year and age groups. We assumed 
that the tuberculosis notification rates were flat within each age group (0-4, 5-14, 15-24, 25-34, 35-44, 
45-54, 55-64, and 65+ years) separately for each sex, and applied these rates to the single-year age 
group population estimates. 
 
To estimate the proportion of cases living with HIV, we focussed on the set of countries with 
population over 1 million in 2020 where the Institute of Health Metrics and Evaluation (IHME) 
estimated HIV prevalence exceeded 1% in at least one age group between 1990 - 2017. For these 
countries we extrapolated WHO estimates of the proportion of tuberculosis cases with HIV between 
2000 and 2017 to the range 1980 - 2019 using a Kalman smoother, together with an assumed 
proportion of 10-10 prior to 1980. HIV-associated tuberculosis cases were disaggregated by age and 
sex proportional to estimated HIV-prevalence in each group and sex.  
 
Numbers surviving untreated tuberculosis episodes 
To account for those who have survived tuberculosis without receiving ATT, we made use of WHO 
estimates of tuberculosis incidence 2000 - 2018. We took the gap between incidence and new and 
relapse notifications to represent the number in each country and year with untreated tuberculosis, and 
used the ratio of new to relapse cases derived from notification data to exclude relapse tuberculosis 
cases. WHO incidence estimates were extrapolated forwards one year using a Kalman smoother and 
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prior to 2000 we assumed incidence followed trends in notifications. Countries where tuberculosis 
notifications in 2000 divided by notifications in some year prior to 2000 exceeded the mean of this 
quantity across all country years by more than three standard deviations (9 countries) were considered 
outliers; we assumed their incidence was constant between 1980 and 2000. We again used the 
extrapolated WHO estimates of HIV prevalence in incident tuberculosis to determine the fraction of 
cases that were HIV-associated, disaggregating this by age and sex proportional to HIV prevalence in 
each category. We computed an ART coverage among those living with HIV by extrapolating 
UNAIDS coverage estimates with a Kalman smoother. 
 
To capture differential tuberculosis detection among children, we used ratios of WHO new and 
relapse notifications to tuberculosis incidence for 0-4, 5-14 and 15+ year age groups in each country 
to compute a relative risk of not receiving tuberculosis treatment compared to adults. These relative 
risks were used to up-weight each age group’s fraction of tuberculosis notifications to generate the 
fraction of incidence in each age group.  
 
Case-fatality ratios for untreated tuberculosis were modelled differently for 0-4, 5-14 and 15+ year 
age groups, and by HIV/ART status. We used the same case-fatality ratios as the WHO estimation 
process, which are based on systematic reviews of pre-chemotherapy literature for HIV-negative 
individuals, and a mixture of literature, programme data and expert opinion for people with HIV (see 
Appendix).  
Survival after tuberculosis episodes 
For the country-, sex- and age-specific baseline mortality rate over time, we used WPP19 estimates, 
and undertook bilinear interpolation to obtain the force of mortality by age and time at single year 
resolution.  
 
For those who survived tuberculosis, we assumed the force of mortality was a factor 2.91 (2.21 - 3.84) 
times higher than in those who had never had tuberculosis, based on Romanowski et al:3 a systematic 
review and meta-analysis of relative all-cause mortality after anti-tuberculosis treatment.  We applied 
this hazard ratio independent of country, time, sex, age, HIV-status and also whether anti-tuberculosis 
treatment was received or not. Sensitivity analyses included using values of 2 and 4, and considering a 
linear decline to no effect between 5 and 10 years after tuberculosis. 
 
For the countries where we explicitly modelled HIV (see above), we estimated HIV-specific mortality 
by country, sex, age and time. To do this, we first extrapolated IHME prevalence estimates by 
country, age, and sex to include the years 1975 - 2020. We fitted cubic splines to the log prevalences 
between 1990 - 2018 appending a point in 1975 with prevalence of 10-10, and predicted prevalence in 
other years. We then estimated a force of mortality in HIV-negative individuals by identifying the 
‘bumps’  over calendar time for each country, sex and age group due to HIV as the period from when 
the force of mortality first increased up to 2050, and interpolating the force of mortality with the 
bump removed using a log-linear trend. We neglected HIV in those aged over 80 years. The excess 
mortality in a given country, year, sex and age group was assumed due to HIV, based on the 
extrapolated IHME HIV prevalence estimates. For these countries, this procedure yielded separate 





This approach allowed us to calculate for each country the number of new tuberculosis cases 
occurring 1980 - 2019, the numbers who received ATT or went untreated, and for each treatment 
group, the life-years lived after tuberculosis up to 2020 and the number of people still alive in 2020. 
We also calculated the number who had survived tuberculosis after treatment in the last 5 or 2 years, 
and stratified results by age and sex. Results were aggregated to a global or WHO region level. 
Uncertainty in outputs was computed by propagating variances associated with inputs through 
calculations analytically. Uncertainty for aggregate quantities in a country was assumed to be 
perfectly correlated over time, but uncorrelated with other countries. All code and input data required 
to reproduce this analysis are publicly available (see Appendix). 
 
Role of the funding source  
The funding source had no role in the design of this study and did not have any role during its 





We estimate that between 1980-2019, a total of 363 million (95% uncertainty interval [UI] 287 - 438 
million) people globally developed new tuberculosis disease, of whom 172 million (95%UI  169 - 174 
million) initiated treatment (Table 1).  Individuals who developed tuberculosis between 1980-2019 
lived 3 480 million (95%UI 3 040 - 3 920 million) life-years post-tuberculosis by 2020 (Figure 2).  
Those who developed tuberculosis when they were <15 years old contributed 12% (95%UI 7 - 17%) 
of the post-tuberculosis life-years lived in this period. 
 
We estimate that 155 million (95%UI  138 - 171 million) people who had had new tuberculosis 
disease and survived that disease episode were still alive in 2020.  Of these, 96 million (95%UI  89 - 
104 million) had initiated treatment and 58 million (95%UI  43 - 73 million) were never treated. The 
WHO South East Asia region had the largest population of tuberculosis survivors alive in 2020, 
reflecting the burden of tuberculosis cases: 47% (95%UI 37 - 57%) of the total. Among tuberculosis 
survivors alive in 2020, 59% (95%UI 49 - 69%) were male, and the median and interquartile range 
(IQR) for current age of tuberculosis survivors alive in 2020 were 45 (33 - 57) years (Figure 3).  
Furthermore, 8% (95%UI  6 - 10%) were people who had HIV at the time that they developed new 
tuberculosis. On average, tuberculosis survivors alive in 2020 had lived a median (IQR) 12 (6 - 21) 
years after their first tuberculosis episode. 
 
Among tuberculosis survivors alive in 2020, 18% (95%UI 16 - 20%) were treated in the past 5 years, 
including 8% (95%UI 7 - 9%) treated in the past 2 years (Table 2).  Among this relatively accessible 
group of those treated in the past 5 years, 62% (95%UI 57 - 66%) were male, and the median (IQR) 
for current age was 38 (26 - 52) years. In the WHO Eastern Mediterranean region, over 10% of 
recently treated tuberculosis survivors alive in 2020 were children <15 years old, a figure largely 
driven by Pakistan, which accounts for around 70% of case notifications in the region (see Appendix). 
In the WHO Africa region, 44% (95%UI  18 - 69%)  of the tuberculosis survivors alive in 2020 and 
treated in the past 5 years were people who had HIV at the time that they developed tuberculosis, 
suggesting that they could be reached through HIV programs.  
 
Varying mortality hazard ratios between 2 and 4 changed central estimates of survivors by 
approximately 10%; assuming a declining hazard ratio increased estimates by up to 20%  (see 
Appendix). Intermediate and supplementary results are available in the Appendix. 
    
 
     
     
    







This study provides the first comprehensive estimate of the global number of tuberculosis survivors; 
we estimate that 155 million individuals are alive today who developed tuberculosis between 1980-
2019. This is a conservative estimate of all tuberculosis survivors as some individuals alive today will 
have developed tuberculosis prior to 1980. Approximately 27 million tuberculosis survivors who were 
treated within the past five years are a relatively accessible group that could be identified, evaluated 
for post tuberculosis morbidity, provided with appropriate clinical care, and supported financially and 
psychologically. Since 2017, the WHO has published estimates of lives saved by tuberculosis 
programs, most recently stating that 58 million lives were saved between 2000-2018.1  Our study 
presents a complementary estimate, which quantifies the total population of tuberculosis survivors 
alive today. Knowing the number of tuberculosis survivors is also a first step toward applying a 
disability-adjusted life-year framework to fully quantify the burden of tuberculosis, as has recently 
been advocated.15 Given that the total population of tuberculosis survivors is over ten times greater 
than the number estimated to develop tuberculosis disease every year, even a modest level of post-
recovery disability has major implications for tuberculosis morbidity estimates. 
 
Within the large population of tuberculosis survivors that we estimate to be alive today, many 
individuals have complex health needs that are not being addressed by current health systems. A prior 
episode of tuberculosis increases the risk of recurrent tuberculosis disease compared to the 
tuberculosis naïve population,2,16 with higher risks of unfavourable treatment outcomes.17  Chronic 
respiratory symptoms experienced by many post-tuberculosis patients may complicate the diagnosis 
of recurrent tuberculosis versus other respiratory conditions.18  To ensure that tuberculosis survivors 
receive appropriate clinical care, active clinical surveillance of tuberculosis survivors should adopt a 
multidisciplinary approach that involves not only tuberculosis programs but non-communicable 
disease clinics, such as those that manage chronic respiratory diseases. Where available, lung function 
evaluation could be undertaken to identify a variety of  lung function impairments, with appropriate 
initiation of, for example, inhaled bronchodilator, prophylactic antibiotics or steroid therapy. Even in 
settings with limited health system capacity for managing chronic respiratory conditions, 
interventions such as pneumococcal vaccination, pulmonary rehabilitation, and promotion of smoking 
cessation could help mitigate the impact of ongoing respiratory morbidity and improve quality of life 
for tuberculosis survivors. 
 
We estimate that 12% of the post-tuberculosis life years experienced globally were due to tuberculosis 
during childhood. Although limited data are available on the long-term consequences of tuberculosis 
in children, there is clear evidence that impaired early lung function persists throughout life.19–21  
Therefore, it is likely that a chronic lung infection like tuberculosis experienced in childhood will 
exert a lifelong impact on lung function. Other lower respiratory tract infections during infancy have 
been shown to reduce lung function in childhood.22,23  Moreover, studies have found prior history of 
pulmonary tuberculosis or severe lower respiratory tract infection to be independently associated with 
worse lung function in adolescents.24,25 It therefore follows that protecting lung growth and capacity 
early in life is critically important for outcomes later in life. In the context of tuberculosis this means 
improving prevention and early diagnosis in childhood.  
 
In addition to the health consequences, it is important to consider the financial impact on individuals 
with  tuberculosis disease, especially given that many are already living in poverty. These costs can be 
catastrophic and long-lasting, impacting both patients and their family members.11–14  Social 
protection programs providing money, food, or services like housing could mitigate these long-term 
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consequences in addition to reducing the direct and indirect costs of treatment in the short term. An 
example of this is Brazil’s Bolsa Familia program which has been shown to improve tuberculosis 
treatment outcomes, in large part by reducing barriers to continuity of care.26,27  It is important to 
explore whether these programs can help patients avoid catastrophic costs and future socio-economic 
repercussions after treatment.28  
 
Given the large number of tuberculosis survivors alive today, our results highlight several areas of 
research importance for understanding the long-term impact that tuberculosis exerts on these 
survivors. Post-tuberculosis structural lung pathology and respiratory morbidity remain poorly defined 
and understood.29  There is a critical need for large prospective cohort studies, including both children 
and adults, to determine the evolution of post-tuberculosis lung damage and its associated morbidity, 
including exercise capacity and health-related quality of life assessments. More mechanistic studies 
are required to understand the pathophysiology of post-tuberculosis lung impairment, which could 
better define and inform therapies to prevent or treat this condition. Current clinical trials of new 
tuberculosis treatments are largely focused on recurrence-free survival outcomes with limited 
consideration for lung health and quality of life post tuberculosis. The large burden of tuberculosis 
survivors highlights the need for trials to additionally assess the impact of therapy on post-treatment 
morbidity and not only microbiological cure. Finally, more research is required to better understand 
which interventions might be most effective in alleviating the financial and stigmatizing effects of 
having had tuberculosis.  
 
Our study has several important limitations. Notification data reported to WHO were not available for 
2019 and WHO only estimated incidence from 2000 onwards. These and other missing data required 
imputation. We employed the widely-used WHO estimates of tuberculosis incidence, which include 
the HIV-associated fraction; these estimates have their own limitations. Our assumption that non-
notified tuberculosis was not treated may underestimate survivors in countries with large private 
sectors or incomplete reporting systems. Our approach to HIV and ART was also limited by the 
available data; we used IHME estimates to inform age- and sex-specific prevalence, but had to 
extrapolate estimates to earlier years. We also did not specifically differentiate drug-resistant 
tuberculosis. We may underestimate survivor numbers by not accurately accounting for recurrent 
tuberculosis in previously untreated individuals who receive treatment for their second episode. 
However, we estimate this effect is limited to a few percent.  
 
A key parameter is the mortality hazard ratio for survival post the tuberculosis episode, which we took 
from Romanowski et al.3 This pooled estimate is subject to large heterogeneity, and is specific to 
survivors of tuberculosis treatment. We applied it to both treated and untreated survivors and did not 
consider heterogeneity by age or setting. However, our sensitivity analyses around this parameter 
show our estimates are robust to reasonable variation, particularly for those recently treated. Overall 
uncertainty in  our estimates of treated survivors is largely driven by this hazard ratio. Estimates of 
untreated survivors are more uncertain since they additionally rely on uncertain incidence estimates 
and uncertain case-fatality ratios for the tuberculosis episode. Finally, limitations in estimates of input 
uncertainty, and particularly their correlations, mean our uncertainty results are less robust than our 
central estimates. 
 
Over 150 million individuals are alive today who have survived tuberculosis, many of whom 
experience substantial health, financial and social consequences that are currently poorly understood 
and therefore not addressed by health and social care systems. Some existing interventions could be 
used to prevent recurrent tuberculosis (such as tuberculosis preventive therapy) and reduce future 
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mortality. In addition, interventions are also available that may alleviate some of the patterns of 
respiratory morbidity. These interventions, as well as active screening for recurrent tuberculosis, 
should be immediately prioritized for recently treated tuberculosis survivors, who should be relatively 
identifiable by health systems. In addition, far more research is required to better understand the 
tuberculosis survivor population and develop new interventions to prevent or treat post tuberculosis 
morbidity.  Finally, monitoring of tuberculosis survivors should be incorporated into recording and 
reporting systems, as India has done by requiring six-monthly follow-up evaluations of tuberculosis 
survivors for 2 years after treatment. While it will take time for health systems to build capacity to 
implement long-term monitoring, adopting long-term indicators is an important step toward ensuring 
that the health of tuberculosis survivors is  considered an integral part of the tuberculosis care cascade, 
and that the journey does not end with treatment completion. 
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Table 1: Global and regional new tuberculosis cases, new cases treated,  life-years lived 1980-
2020, and tuberculosis survivors in 2020 
 
 Africa The Americas 
Eastern 
Mediterranean 





72 400 000 ( 60 
800 000 - 84 
000 000) 
11 500 000 ( 10 
700 000 - 12 
400 000) 
25 600 000 ( 2 
230 000 - 48 
900 000) 
14 300 000 ( 12 
200 000 - 16 
300 000) 
161 000 000 ( 
95 100 000 - 
227 000 000) 
77 800 000 ( 51 
800 000 - 104 
000 000) 
363 000 000 ( 
287 000 000 - 





32 300 000 ( 31 
900 000 - 32 
700 000) 
9 120 000 ( 9 
000 000 - 9 230 
000) 
12 500 000 ( 12 
400 000 - 12 
600 000) 
12 000 000 ( 11 
800 000 - 12 
100 000) 
68 500 000 ( 66 
500 000 - 70 
500 000) 
37 300 000 ( 36 
400 000 - 38 
200 000) 
172 000 000 ( 
169 000 000 - 






39 800 000 ( 36 
100 000 - 43 
500 000) 
2 320 000 ( 2 
200 000 - 2 440 
000) 
13 300 000 ( 8 
810 000 - 17 
900 000) 
2 350 000 ( 2 
050 000 - 2 640 
000) 
92 000 000 ( 70 
800 000 - 113 
000 000) 
39 900 000 ( 29 
800 000 - 49 
900 000) 
190 000 000 ( 
166 000 000 - 





499 000 000 ( 
378 000 000 - 
620 000 000) 
147 000 000 ( 
143 000 000 - 
151 000 000) 
286 000 000 ( 
199 000 000 - 
374 000 000) 
181 000 000 ( 
175 000 000 - 
188 000 000) 
1 590 000 000 
(1 230 000 000 
- 1 960 000 
000) 
771 000 000 ( 
588 000 000 - 
955 000 000) 
3 480 000 000 
(3 040 000 000 








267 000 000 ( 
164 000 000 - 
370 000 000) 
127 000 000 ( 
123 000 000 - 
130 000 000) 
166 000 000 ( 
160 000 000 - 
171 000 000) 
160 000 000 ( 
157 000 000 - 
163 000 000) 
794 000 000 ( 
757 000 000 - 
832 000 000) 
421 000 000 ( 
408 000 000 - 
434 000 000) 
1 940 000 000 
(1 820 000 000 









232 000 000 ( 
168 000 000 - 
295 000 000) 
20 200 000 ( 18 
000 000 - 22 
400 000) 
121 000 000 ( 
33 400 000 - 
208 000 000) 
21 200 000 ( 15 
400 000 - 26 
900 000) 
801 000 000 ( 
434 000 000 - 1 
170 000 000) 
350 000 000 ( 
167 000 000 - 
533 000 000) 
1 540 000 000 
(1 120 000 000 






25 700 000 ( 18 
600 000 - 32 
800 000) 
5 510 000 ( 5 
320 000 - 5 700 
000) 
12 600 000 ( 9 
430 000 - 15 
800 000) 
6 710 000 ( 6 
460 000 - 6 960 
000) 
72 200 000 ( 58 
700 000 - 85 
700 000) 
31 900 000 ( 26 
600 000 - 37 
200 000) 
155 000 000 ( 
138 000 000 - 





15 200 000 ( 8 
460 000 - 21 
900 000) 
4 780 000 ( 4 
610 000 - 4 950 
000) 
7 750 000 ( 7 
470 000 - 8 030 
000) 
6 020 000 ( 5 
820 000 - 6 220 
000) 
41 700 000 ( 39 
500 000 - 43 
900 000) 
21 000 000 ( 20 
200 000 - 21 
900 000) 
96 400 000 ( 89 






10 500 000 ( 8 
200 000 - 12 
800 000) 
734 000 ( 653 
000 - 815 000) 
4 870 000 ( 1 
690 000 - 8 060 
000) 
693 000 ( 540 
000 - 846 000) 
30 500 000 ( 17 
200 000 - 43 
900 000) 
10 800 000 ( 5 
580 000 - 16 
100 000) 
58 200 000 ( 43 





Table 2: Global and regional tuberculosis survivors in 2020 treated within 5 and 2 years 
 
Region Total % male 
% under 
15 years 
old Total % male 
% under 15 years 
old 
 Treated within 5 years Treated within 2 years 
Africa 
4 992 000 ( 3 402 000 - 6 
581 000) 58 7.6 
2 166 000 ( 1 556 000 - 2 
776 000) 59 8.1 
The Americas 957 600 ( 944 200 - 971 100) 62 4.5 
407 500 ( 402 300 - 412 
800) 63 4.8 
Eastern 
Mediterranean 
2 270 000 ( 2 236 000 - 2 
304 000) 51 10.6 
968 700 ( 958 400 - 979 
100) 51 11.7 
Europe 
977 500 ( 942 100 - 1 013 
000) 65 3.5 
376 700 ( 359 600 - 393 
700) 65 3.9 
South-East 
Asia 
12 420 000 (12 240 000 - 12 
610 000) 62 6.0 
5 764 000 ( 5 706 000 - 5 
822 000) 62 6.6 
Western 
Pacific 
5 794 000 ( 5 693 000 - 5 
895 000) 66 3.7 
2 505 000 ( 2 474 000 - 2 
536 000) 67 4.1 
Global 
27 410 000 (25 810 000 - 29 
020 000) 61 6.0 
12 190 000 (11 570 000 - 










Figure 2: Life-years lived post-tuberculosis 1980-2020 by age at first tuberculosis, sex, region 
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Figure 3
